规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
Akt1 (IC50 = 5 nM); Akt3 (IC50 = 8 nM); Akt2 (IC50 = 18 nM); PKA (IC50 = 3100 nM)
|
---|---|
体外研究 (In Vitro) |
与密切相关的 PKA 和 p70S6K 相比,imatasertib diHClide 对 Akt1 的选择性分别高出 600 倍和 100 倍以上,IC50 值更高。在 230 种蛋白质缀合物(包括人类 AGC 家族的 36 名成员)中,Ipatasertib diHClide 在 1 μM 浓度下仅抑制三种蛋白质缀合物(PRKG1α、PRKG1β 和 p70S6K)超过 70%。 ..对于这三个物种,定期测量的 IC50 值依次为 98、69 和 860 nM。因此,与第二个最有效的非 Akt 抑制剂(上面的 p70S6K Multiples 面板)相比,ipatasertib 二盐酸盐对筛选中的 Akt1 选择性高出 100 倍,但 PKG1 除外(其中 ipatasertib 二盐酸盐对 Akt1 的选择性高出 10 倍以上) 。使用展示药物治疗剂量依赖性反应的三种异种移植模型来研究二盐酸ipatasertib:MCF7-neo的药代动力学(PK)和药效学(PD)之间的关系。 /HER2、TOV-21G.x1 和 LNCaP Ipatasertib diHClide 在这三种细胞系中的平均细胞活力 IC50 分别为 2.56、0.44 和 0.11 μM [2]。
|
体内研究 (In Vivo) |
在 Akt 由 PTEN 缺失、PIK3CA 突变或突变或 HER2 过度表达等遗传变化触发的移植模型中,二盐酸伊马替尼通常会成功。这些模型中的肿瘤在 100 mg/kg 或以下(在免疫功能低下的小鼠中观察到的最大耐受剂量)缓慢发育、生成或恢复。在体内检查中,每天将 RP-56976 与 Ipatasertib diHClide 组合可在 PC-3 和 MCF7-neo/HER2 异种移植小鼠中产生镇痛和肿瘤消退,但毒素本身要么无效,要么只是导致肿瘤发展。逐渐增加剂量。同样,当 Ipatasertib diHClide 和 NSC 241240 偶联时,在 OVCAR3 卵巢癌异种移植模型中观察到 TGI 升高。与额外化疗相比,Ipatasertib diHClide 联合 RP-56976 或 NSC 241240 单独治疗导致体重减轻不到 5% [2]。
|
细胞实验 |
384 孔板每孔接种 2,000 个细胞,体积为 54 L,然后在 37°C、5% CO2 下孵育过夜(大约 16 小时)。为了产生所需的库存浓度,化合物(如 Ipatasertib)在 DMSO 中稀释,然后以每孔 6 L 的体积添加。每种处理均测试四次。孵育四天后,在 Wallac Multilabel Reader 上测量总发光,并使用 CellTiter-Glo 估计相对活力。 4 参数曲线分析 (XLfit) 用于计算产生 IC50 的药物浓度,并且基于至少三个实验的结果。列出了未达到 IC50 的细胞系的最高测试浓度 (10 M)[2]。
|
动物实验 |
Mice:Numerous patient-derived xenograft models and tumor cell line models are used to evaluate in vivo efficacy. Immunocompromised mice have cells or tumor fragments implanted subcutaneously into their flanks. Mice that are severely combined immunodeficient (SCID) or beige, or both, are used. Male mice are castrated prior to the implantation of tumor fragments, and the LuCaP35V patient-derived primary tumors are obtained. When tumor cells or fragments are implanted into mice, the tumors are watched until they reach mean tumor volumes of 180 to 350 mm3 and are then divided into groups of 8 to 10 animals each. Ipatasertib is administered every day (QD) via oral (per os; PO) gavage and is formulated in 0.5% methylcellulose/0.2% Tween-80 (MCT). Every week (QW), 2.5 or 7.5 mg/kg of RP-56976 is administered intravenously (IV) in a solution of 3% EtOH/97% saline. Saline-based NSC 241240 is administered intraperitoneally (IP) once a week at a dose of 50 mg/kg.
|
参考文献 |
[1]. Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27.
[2]. Lin J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013 Apr 1;19(7):1760-72 |
分子式 |
C₂₄H₃₄CL₃N₅O₂
|
---|---|
分子量 |
530.9181
|
精确质量 |
529.1778
|
元素分析 |
C, 54.30; H, 6.46; Cl, 20.03; N, 13.19; O, 6.03
|
CAS号 |
1396257-94-5
|
相关CAS号 |
Ipatasertib;1001264-89-6
|
外观&性状 |
Solid powder
|
SMILES |
O=C(N1CCN(C2=C([C@H](C)C[C@H]3O)C3=NC=N2)CC1)[C@@H](C4=CC=C(Cl)C=C4)CNC(C)C.[H]Cl.[H]Cl
|
InChi Key |
SRKVNRNRVFDUTG-VISIQVHMSA-N
|
InChi Code |
InChI=1S/C24H32ClN5O2.2ClH/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H32*1H/t16-,19-,20-/m1../s1
|
化学名 |
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-onedihydrochloride
|
别名 |
Ipatasertib dihydrochloride; Ipatasertib; GDC 0068; GDC-0068; GDC0068; RG7440; RG 7440; RG-7440
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: ~100 mg/mL (188.35 mM; Need ultrasonic)
H2O: ≥41 mg/mL (77.22 mM) |
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 3.88 mg/mL (7.31 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.88 mg/mL (7.31 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.08 mg/mL (3.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 2.08 mg/mL (3.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 6: 16.67 mg/mL (31.40 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8835 mL | 9.4176 mL | 18.8352 mL | |
5 mM | 0.3767 mL | 1.8835 mL | 3.7670 mL | |
10 mM | 0.1884 mL | 0.9418 mL | 1.8835 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Status | Interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02465060 | Active Recruiting |
Drug: Adavosertib Drug: Afatinib Drug: Afatinib Dimaleate |
Bladder Carcinoma Breast Carcinoma |
National Cancer Institute (NCI) |
August 12, 2015 | Phase 2 |